An observational study in Coronary Artery Disease, sponsored by Baker Heart and Diabetes Institute. Recruiting at 2 sites in Australia. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Baker Heart and Diabetes Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Coronary Artery Disease with a site in Australia — 11 open to participants now, 17 under way, 4 of them phase 3. Coronary Artery Disease · Australia.
Among the 89 studies in Coronary Artery Disease with a site in Australia, this one is one of 5 that started in 2023, is one of 7 observational ones, reaches primary completion later than 1 of the 16 other live ones, and was the 78th registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →11 of the 89 studies in Coronary Artery Disease with a site in Australia are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, United States, Germany and 2 more countries
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in Australia, United States, Canada and 1 more country
Ages 18–80
Verve Therapeutics, Inc. · Sites in Australia, United States, Canada and 3 more countries
Ages 18–70
CSL Behring · Sites in Australia, United States, Argentina and 32 more countries
Ages 18+
Weill Medical College of Cornell University · Sites in Australia, United States, Austria and 23 more countries
Ages 18+ · Women only
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 29 · Phase 4 5
First in 1996; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 748 is above the median of 326 across 1,689 observational studies indexed under Coronary Artery Disease.
Median enrollment 626 across the 82 interventional studies, 1,106 across the 7 observational. Of the 63 that completed or were terminated, 35 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 89 have an industry lead sponsor. The 10 most frequent:
Baker Heart and Diabetes Institute is the lead sponsor of 26 studies on the registry; 8 are open to participants now.
Baker Heart and Diabetes Institute has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Coronary Artery Disease with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06890507University of AdelaideThe Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA) | 2027-04-01 |
| NCT07521007Beijing Inno Medicine Co., Ltd.A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis | 2027-07-31 |
| NCT07830719Novartis PharmaceuticalsDose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | 2027-08-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 89 studies in Coronary Artery Disease with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago.
REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago. The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD. This unique Screening/Management Plan (SMP) has 2 components; 1) A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2) A clinical review to ensure optimal risk factor control and cardio protection.
Follow-up of treated patients will continue for an average of 36 months, with clinic reviews at 12, 24 and 36 months. The results will define the prevalence of subclinical coronary artery disease, and the feasibility and the efficacy of the SMP.
Cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A history of cancer >5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In cancer survivors; 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.
Diagnostic Test: Coronary CT
In matched non-cancer patients (from EDCAD trial); 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.
Diagnostic Test: Coronary CT
Screening/Management Plan
Proportion of evaluated patients who should undergo CAD prevention
High clinical risk, or intermediate risk with CAC score \>0
Time frame: 3 years
Proportion with critical CAD
Coronary stenosis \>70% by CT coronary angiogram
Time frame: 3 years
Proportion at intermediate clinical risk
Intermediate clinical risk (0.8-2.0% annualized risk by Pooled Cohort Equation)
Time frame: 3 years
Statin responsiveness
Change in plaque volume
Time frame: 3 year follow-up
Started Oct 2023 (actual). Primary completion is estimated for May 2026, 31 months after the start.
Of 636 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 31 months is below that.
Counting every sponsor, half of 761 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baker Heart and Diabetes Institute